Krystal Biotech, Inc.
(NASDAQ : KRYS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 1.14%33.840.9%$1138.25m
JNJJohnson & Johnson 0.01%142.500.7%$1016.34m
BMYBristol-Myers Squibb Co. -1.17%57.431.0%$922.01m
MRKMerck & Co., Inc. 0.05%76.730.7%$787.68m
ABBVAbbVie, Inc. -1.18%96.781.9%$725.30m
LLYEli Lilly & Co. -1.84%163.391.1%$641.93m
AZNAstraZeneca Plc -0.40%53.761.2%$288.49m
RPRXRoyalty Pharma Plc -1.49%47.640.1%$203.76m
NVSNovartis AG -0.36%87.030.2%$143.34m
RGENRepligen Corp. -1.97%126.137.1%$115.34m
GSKGlaxoSmithKline Plc -1.14%39.910.2%$109.88m
NVONovo Nordisk A/S -0.26%65.440.1%$88.47m
RETAReata Pharmaceuticals, Inc. -1.10%154.403.4%$79.42m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -2.31%74.140.0%$67.56m
SNYSanofi -0.53%50.280.2%$63.74m

Company Profile

Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.